Search company, investor...
REGiMMUNE company logo


Founded Year



Series D | Alive

Total Raised


Last Raised

$9.2M | 9 yrs ago


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

Headquarters Location

14-10 Kodenma-cho 9F Chuou-ku

Tokyo, 103-0001,


Missing: REGiMMUNE's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: REGiMMUNE's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing REGiMMUNE

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

REGiMMUNE is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items


REGiMMUNE has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Dictionary of chemical formulas
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Immune system, Dictionary of chemical formulas, Immunology, Clusters of differentiation, Prodrugs


Application Date


Grant Date



Related Topics

Immune system, Dictionary of chemical formulas, Immunology, Clusters of differentiation, Prodrugs



Latest REGiMMUNE News

REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting

Nov 7, 2022

November 07, 2022 02:54 AM Eastern Standard Time TAIPEI, Taiwan--( BUSINESS WIRE )--REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 12, 2022. This is an open label, single-arm Phase 2 study, evaluating the safety and efficacy of RGI-2001 for the prevention of aGVHD in subjects following allogeneic hematopoietic stem cell transplantation (HSCT). This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT. The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications. “Based on the analysis, RGI-2001 showed reduced incidence of aGVHD with an excellent safety profile. I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting. We look forward to sharing future findings as we work to deliver breakthrough immune medicines by harnessing the power of regulatory T cells,” said Kenzo Kosuda, CEO at REGiMMUNE Limited. Session Name: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease Session Date and Time: Monday, December 12, 2022, 10:30 - 12:00 p.m. CT Presentation time: 11:45 a.m. CT Location: Ernest N. Morial Convention Center, 252-254 and online Presenter: Yi-Bin Chen, MD

REGiMMUNE Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo


REGiMMUNE Frequently Asked Questions (FAQ)

  • When was REGiMMUNE founded?

    REGiMMUNE was founded in 2006.

  • Where is REGiMMUNE's headquarters?

    REGiMMUNE's headquarters is located at 14-10 Kodenma-cho 9F, Tokyo.

  • What is REGiMMUNE's latest funding round?

    REGiMMUNE's latest funding round is Series D.

  • How much did REGiMMUNE raise?

    REGiMMUNE raised a total of $40M.

  • Who are the investors of REGiMMUNE?

    Investors of REGiMMUNE include Japan Asia Investment Group, SMBC Venture Capital, Mitsubishi UFJ Capital, KSP, Mitsui Sumitomo Insurance and 19 more.

  • Who are REGiMMUNE's competitors?

    Competitors of REGiMMUNE include ChemoCentryx, La Jolla Pharmaceutical Company, Array Biopharma, Ocera Therapeutics, Dendreon, Dyax, ActoGeniX, Decimmune Therapeutics, Versartis, Trevena and 23 more.

Compare REGiMMUNE to Competitors

Dare Bioscience

Dare Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide.

Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

Iconic Therapeutics

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.


LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.